Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TLR4 | O00206 | 1/20 | 0.34 |
| ▸ | KDM1A | O60341 | 1/20 | 0.34 |
| ▸ | ULK1 | O75385 | 3/20 | 0.33 |
| ▸ | SMYD3 | Q9H7B4 | 6/20 | 0.32 |
| ▸ | TRPM8 | Q7Z2W7 | 3/20 | 0.31 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.30 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.30 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.30 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.30 |
| ▸ | ANPEP | P15144 | 1/20 | 0.30 |
| ▸ | CES2 | O00748 | 1/20 | 0.30 |
| ▸ | CES1 | P23141 | 1/20 | 0.30 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25769017 | 1.00 | TLR4 (0.34) | TLR4KDM1AULK1SMYD3TRPM8 | |
| SCHEMBL8285949 | 0.90 | TLR4 (0.37) | TLR4SMYD3 | |
| SCHEMBL25769031 | 0.90 | TLR4 (0.37) | TLR4SMYD3 | |
| SCHEMBL22519397 | 0.81 | — | — | |
| SCHEMBL256032 | 0.80 | — | — | |
| SCHEMBL12826153 | 0.78 | ACE (0.41) | ANPEP | |
| SCHEMBL23960485 | 0.77 | KDM1A (0.36) | TLR4KDM1AULK1SMYD3CES2 | |
| SCHEMBL8284979 | 0.77 | KDM1A (0.36) | TLR4KDM1AULK1SMYD3CES2 | |
| SCHEMBL25648881 | 0.77 | KDM1A (0.36) | TLR4KDM1AULK1SMYD3CES2 | |
| SCHEMBL16199056 | 0.77 | KDM1A (0.36) | TLR4KDM1AULK1SMYD3CES2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090280106-A1 | Pituitary adenylate cyclase acivating peptide (pacap) receptor (vpac2) agonists and their pharmacological methods of use | BAYER PHARMACEUTICALS CORPORATION (US) | 2009-11-12 | — | — | US | disclosed |
| WO-2005053726-A1 | SELECTIVE NEUROPEPTIDE Y2 RECEPTOR AGONISTS | BAYER PHARMACEUTICALS CORPORATION (US) | 2005-06-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090280106-A1 | Pituitary adenylate cyclase acivating peptide (pacap) receptor (vpac2) agonists and their pharmacological methods of use | ADCYAP1R1, VIPR2, ADCY2 | TLR4 2720/4885KDM1A 3635/4885ULK1 3196/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.